# Hospira

# SAFETY DATA SHEET



Revision date 05-Apr-2022 Version 2 Page 1/14

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Product Code(s) PZ03383
Trade Name: Not applicable
Chemical Family: Not determined

# 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical active used as opioid analgesic

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045

Lake Forest, Illinois 60045 1-800-879-3477 Pfizer Ireland Pharmaceuticals

OSG Building

Ringaskiddy, Co. Cork.

Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

# 1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

# Section 2: HAZARDS IDENTIFICATION

# 2.1. Classification of the substance or mixture

GHS - Classification

Germ cell mutagenicityCategory 2 - (H341)Reproductive toxicityCategory 1B - (H360D)Effects on or via lactationYes - (H362)

2.2. Label elements

Signal word Danger

Hazard statements H360D - May damage the unborn child

H362 - May cause harm to breast-fed children H341 - Suspected of causing genetic defects

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Revision date 05-Apr-2022 Version 2

**Precautionary Statements** 

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required P260 - Do not breathe dust/fume/gas/mist/vapors/spray P263 - Avoid contact during pregnancy/while nursing

P264 - Wash hands thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P308 + P313 - IF exposed or concerned: Get medical attention/advice



An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

# Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances **Substances** 

Not applicable

# 3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Morphine Sulfate (CAS #: 64-31-3)	1-2.5		200-582-8	Acute Tox. 4 (H302) Repr. 1B (H360D) Lact. (H362) Muta. 2 (H341)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331)	Eye Irrit. 2 :: 10%<=C<25%	No data available	No data available

Page 2/14

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Revision date 05-Apr-2022 Version 2

				Skin Corr. 1A (H314) Press. Gas	Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%		
Sodium metabisulfite USP (CAS #: 7681-57-4)	<1.0		231-673-0	Acute Tox. 4 (H302) Eye Dam. 1 (H318)	Not Listed	No data available	No data available
NonHazardous							
Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available

# Full text of H- and EUH-phrases: see section 16

# **Acute Toxicity Estimate**

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Morphine Sulfate 64-31-3	461	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022
Sodium metabisulfite USP 7681-57-4	1310	2000	No data available	No data available	No data available

### **Additional information**

- + Substance with a Union workplace exposure limit
- \* Proprietary
- \*\* to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

# Section 4: FIRST AID MEASURES

# 4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

PZ03383

Page 3/14

antioxidant (Hospira, Inc.) Revision date 05-Apr-2022 Version 2

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do Ingestion

not induce vomiting unless directed by medical personnel. Seek medical attention

Page 4/14

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Product Name Morphine Sulfate Injection - preservative-free, contains

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Not applicable.

**Hazardous combustion products** Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and

other sulfur-containing compounds.

5.3. Advice for firefighters

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Personal precautions

Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Sweep spilled material into an approved container for disposal keeping dust generation to a

Methods for cleaning up Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible

absorbent material and transfer into a labeled container for disposal.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Revision date 05-Apr-2022 Version 2

# Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

### Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

# Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium hydroxide

ACGIH OEL (Ceiling)  $2 \text{ mg/m}^3$ **ACGIH TLV** Ceiling: 2 mg/m<sup>3</sup> 2 mg/m<sup>3</sup> Austria STEL 4 mg/m<sup>3</sup> Bulgaria 2.0 mg/m<sup>3</sup> 1 mg/m<sup>3</sup> Czech Republic Ceiling: 2 mg/m<sup>3</sup>

Denmark Ceiling: 2 mg/m<sup>3</sup> Estonia 1 mg/m<sup>3</sup> STEL: 2 mg/m<sup>3</sup>

Ceiling: 2 mg/m3 Finland 2 mg/m<sup>3</sup> France 1 mg/m<sup>3</sup> Hungary STEL: 2 mg/m<sup>3</sup>

STEL: 2 mg/m<sup>3</sup> Ireland Ceiling Limit Value 2 mg/m<sup>3</sup> Latvia 0.5 mg/m<sup>3</sup> Poland STEL: 1 mg/m<sup>3</sup>

0.5 ma/m3 Romania 1 ma/m<sup>3</sup> STEL: 3 mg/m3

Slovakia 2 mg/m<sup>3</sup> STEL: 2 mg/m3 Spain 2 mg/m<sup>3</sup> Switzerland STEL: 2 mg/m3

OSHA PEL 2 mg/m<sup>3</sup> (vacated) Ceiling: 2 mg/m<sup>3</sup>

STEL: 2 mg/m3 United Kingdom

+ Hydrochloric Acid

ACGIH OEL (Ceiling) 2 ppm

PZ03383

Page 5/14

Page 6/14

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)
Revision date 05-Apr-2022

Version 2

	•	
۸.		Callings 2 ppm
_	GIH TLV stria	Ceiling: 2 ppm
Aus	ына	5 ppm 8 mg/m³
		STEL 10 ppm
		STEL 15 mg/m <sup>3</sup>
Bul	garia	STEL: 10 ppm
	94.14	STEL: 15.0 mg/m <sup>3</sup>
		5 ppm
		8.0 mg/m <sup>3</sup>
Cze	ech Republic	8 mg/m³
		Ceiling: 15 mg/m <sup>3</sup>
Est	onia	5 ppm
		8 mg/m <sup>3</sup>
		STEL: 10 ppm
_	11.	STEL: 15 mg/m <sup>3</sup>
Eur	ropean Union	TWA: 5 ppm
		TWA: 8 mg/m <sup>3</sup> STEL: 10 ppm
		STEL: 10 ppin STEL: 15 mg/m <sup>3</sup>
Finl	land	STEL: 15 mg/m²
	idild	STEL: 7.6 mg/m <sup>3</sup>
Ger	rmany	2 ppm
00.		3.0 mg/m <sup>3</sup>
		Ceiling / Peak: 4 ppm
		Ceiling / Peak: 6 mg/m <sup>3</sup>
Ger	rmany	2 ppm
		3 mg/m³
Hur	ngary	8 mg/m³
		STEL: 16 mg/m <sup>3</sup>
Irela	and	8 mg/m <sup>3</sup>
		5 ppm
		STEL: 10 ppm STEL: 15 mg/m <sup>3</sup>
Italy	M.	5 ppm
ital	y	8 mg/m <sup>3</sup>
		STEL: 10 ppm
		STEL: 15 mg/m <sup>3</sup>
Cei	ling Limit Value	2 ppm
	•	3.0 mg/m <sup>3</sup>
Lat	via	5 ppm
		8 mg/m³
		STEL: 10 ppm
		STEL: 15 mg/m <sup>3</sup>
Net	therlands	8 mg/m <sup>3</sup>
Dol	and	STEL: 15 mg/m <sup>3</sup> STEL: 10 mg/m <sup>3</sup>
FOI	anu	5 mg/m <sup>3</sup>
Ror	mania	5 ppm
1101	mama	8 mg/m <sup>3</sup>
		STEL: 10 ppm
		STEL: 15 mg/m <sup>3</sup>
Rus	ssia	MAC: 5 mg/m <sup>3</sup>
Slo	vakia	5 ppm
		8.0 mg/m <sup>3</sup>
Spa	ain	5 ppm
		7.6 mg/m <sup>3</sup>

7.6 mg/m<sup>3</sup> STEL: 10 ppm

STEL: 15 mg/m<sup>3</sup>

Switzerland 2 ppm

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)
Revision date 05-Apr-2022

Revision date 05-Apr-2022 Version 2

3 mg/m<sup>3</sup>

STEL: 4 ppm STEL: 6 mg/m<sup>3</sup>

U.S. - OSHA - Final PELs - Ceiling Limits 5 ppm 7 mg/m<sup>3</sup>

OSHA PEL (vacated) Ceiling: 5 ppm

(vacated) Ceiling: 7 mg/m<sup>3</sup>

Page 7/14

Ceiling: 5 ppm Ceiling: 7 mg/m<sup>3</sup>

United Kingdom TWA: 1 ppm

TWA: 2 mg/m<sup>3</sup> STEL: 5 ppm STEL: 8 mg/m<sup>3</sup>

Sodium metabisulfite USP

 ACGIH TLV
 5 mg/m³

 Denmark
 5 mg/m³

 France
 5 mg/m³

 Ireland
 5 mg/m³

STEL: 15 mg/m<sup>3</sup>

 $\begin{array}{cc} \text{Spain} & \quad 5 \text{ mg/m}^3 \\ \text{Switzerland} & \quad 5 \text{ mg/m}^3 \end{array}$ 

OSHA PEL (vacated) TWA: 5 mg/m<sup>3</sup>

United Kingdom TWA: 5 mg/m³ STEL: 15 mg/m³

**Pfizer Occupational Exposure Band** 

(OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Environmental exposure controls** No information available.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in

the workplace and specific operational processes.

**Eye/face protection** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

**Hand protection** Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible

and for bulk processing operations. (Protective clothing must meet the standards in

accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Revision date 05-Apr-2022 Version 2

exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

Page 8/14

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

# Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state Solution

ColorNo information availableOdorNo information available.Odor thresholdNo information available

Molecular formulaMixtureMolecular weightMixture

<u>Property</u> <u>Values</u>

pHNo data availableMelting point / freezing pointNo data available

Boiling point / boiling range
Flash point
No information available

Evaporation rate

Flammability (solid, gas)

Flammability Limit in Air

No data available

No data available

Upper flammability limit: No data available

Lower flammability limit: No data available

Vapor pressure No data available Vapor density No data available Relative density No data available No data available Water solubility No data available Solubility(ies) No data available Partition coefficient **Autoignition temperature** No data available No data available **Decomposition temperature** No data available Kinematic viscosity No data available **Dynamic viscosity** 

Particle characteristics
Particle Size
Particle Size Distribution
No information available
No information available
No information available
No information available

### 9.2. Other information

No information available

# 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

# Section 10: STABILITY AND REACTIVITY

Product Name Morphine Sulfate Injection - preservative-free, contains Page 9/14 antioxidant (Hospira, Inc.) Revision date 05-Apr-2022

Version 2

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

**Explosion data** 

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

# Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

The information included in this section describes the potential hazards of the individual **General Information:** 

ingredients

Short term May be harmful if swallowed May cause eye irritation (based on components)

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the

developing fetus.

**Known Clinical Effects:** Ingestion of this material may cause effects similar to those seen in clinical use including dry

mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdosage may also lead to respiratory depression,

hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.

**Acute toxicity** 

Serious eye damage/eye irritation

Skin corrosion/irritation Respiratory or skin sensitization STOT - single exposure

STOT - repeated exposure Reproductive toxicity Germ cell mutagenicity Carcinogenicity **Aspiration hazard** 

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

# Acute Toxicity: (Species, Route, End Point, Dose)

Morphine Sulfate

Rat Oral LD50 461 mg/kg

Rat Para-periosteal LD50 70 mg/kg

Rat Intraperitoneal LD50 235 mg/kg

Mouse Oral LD50 600 mg/kg

Mouse Intravenous LD50 156 mg/kg

Sodium hydroxide

Mouse IP LD50 40 ma/ka

Wodac II LDao to Ilig/kg			
Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg(Rat)	-	-
Morphine Sulfate	= 461 mg/kg (Rat)	-	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg ( Rabbit )	-

Product Name Morphine Sulfate Injection - preservative-free, contains

Revision date 05-Apr-2022

+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat)1 h
Sodium metabisulfite USP	= 1310 mg/kg ( Rat )	> 2000 mg/kg ( Rat )	-

Irritation / Sensitization: (Study Type, Species, Severity)

+ Hydrochloric Acid

antioxidant (Hospira, Inc.)

Skin irritation Severe Eye irritation Severe

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Morphine Sulfate** 

18 Week(s) Rat Oral 60 g/kg LOAEL Lungs

15 Day(s) Rat Subcutaneous 3144 mg/kg LOAEL Kidney, Ureter, Bladder

9 Week(s) Rat Subcutaneous 3150 mg/kg LOAEL

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) Morphine Sulfate

Embryo / Fetal Development Mouse Subcutaneous 0.15 mg/kg LOAEL Teratogenic

Embryo / Fetal Development Hamster Subcutaneous 35 mg/kg LOAEL Teratogenic

Embryo / Fetal Development Mouse Oral 200 mg/kg LOAEL Teratogenic

Embryo / Fetal Development Rat Subcutaneous 35 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Morphine Sulfate

In Vivo Micronucleus Mouse Positive

In Vivo Chromosome Aberration Mouse Lymphocytes Positive

In Vitro Direct DNA Damage Human Lymphocytes Positive

In Vitro Chromosome Aberration Mouse Negative

Dominant Lethal Assay Drosophila Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) Salmonella

In Vivo Micronucleus Rat Negative

Carcinogenicity See below

+ Hydrochloric Acid

Group 3 (Not Classifiable) IARC

Sodium metabisulfite USP

IARC Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

11.2.2. Other information

No information available. Other adverse effects

Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties of the formulation have not been thoroughly investigated.

Negative

Releases to the environment should be avoided.

Page 10 / 14

Version 2

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)
Revision date 05-Apr-2022

Page 11 / 14

Version 2

# 12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

12.4. Mobility in soil

Mobility in soil No information available.

# 12.5. Results of PBT and vPvB assessment

### PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does
·	not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does
	not apply
Sodium metabisulfite USP	The substance is not PBT / vPvB PBT assessment does
	not apply

# 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

12.7. Other adverse effects

No information available.

# Section 13: DISPOSAL CONSIDERATIONS

# 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

# Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Page 12/14

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Revision date 05-Apr-2022 Version 2

UN number:
UN proper shipping name:
Not applicable
Transport hazard class(es):
Packing group:
Not applicable
Not applicable
Not applicable
Not applicable

Special precautions for user: Not applicable

# Section 15: REGULATORY INFORMATION

CERCLA/SARA Section 313 de minimus %

# 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-791-2 AICS Present

Morphine Sulfate

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS 200-582-8

Sodium hydroxide

Hazardous Substances RQs
California Proposition 65
Not Listed
TSCA
Present
EINECS
AICS
Present
Standard for Uniform Scheduling of Medicines and
Poisons (SUSMP)

1000 lb
Not Listed
Present
215-185-5
Present
Schedule 5
Schedule 5

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus % 1.0 % **Hazardous Substances RQs** 5000 lb **California Proposition 65** Not Listed Present **TSCA EINECS** 231-595-7 **AICS** Present Schedule 5 Standard for Uniform Scheduling of Medicines and Schedule 6 Poisons (SUSMP)

Sodium metabisulfite USP

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 231-673-0
AICS Present
Standard for Uniform Scheduling of Medicines and Schedule 5

Poisons (SUSMP)

# France

Occupational Illnesses (R-463-3, France)

Occupational linesses (12-405-5, 1 fance)						
Chemical name	French RG number	Title				
Sodium metabisulfite USP	RG 66	-				
7681-57-4						

Not Listed

Product Name Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)
Revision date 05-Apr-2022

Revision date 05-Apr-2022 Version 2

**European Union** 

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

### Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

		<u> </u>	
-	Chemical name	Restricted substance per REACH	Substance subject to authorization per
		Annex XVII	REACH Annex XIV
	Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
	+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	
	Sodium metabisulfite USP - 7681-57-4	Use restricted. See item 75.	

# **Persistent Organic Pollutants**

Not applicable

# Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

# **EU - Biocides**

	5 2.00.000		
	Chemical name	EU - Biocides	
Г	+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algaecides not intend	
		for direct application to humans or animals	

### Leaend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances **AICS** - Australian Inventory of Chemical Substances

# 15.2. Chemical safety assessment

Chemical Safety Report No information available

# Section 16: OTHER INFORMATION

# Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed. Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage. Reproductive toxicity-Cat.1B; H360D - May damage the unborn child. Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children. Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects. Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation. Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage.

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information.

Safety data sheets for individual ingredients.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information.

PZ03383

Page 13/14

antioxidant (Hospira, Inc.)
Revision date 05-Apr-2022 Version 2

Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

Page 14/14

Revision date 05-Apr-2022

Product Name Morphine Sulfate Injection - preservative-free, contains

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

\_\_\_\_